A Multi Center Extension Study of PRX-102 Administered by Intravenous Infusions Every 2 Weeks for up to 60 Months to Adult Fabry Patients
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 22 Mar 2019
Price : $35 *
At a glance
- Drugs Pegunigalsidase alfa (Primary)
- Indications Fabry's disease
- Focus Adverse reactions
- Sponsors Protalix Biotherapeutics
- 18 Mar 2019 Status changed from recruiting to active, no longer recruiting.
- 01 Feb 2018 Treatment arm has been changed fro 3 to 1 and patient number also decreases.
- 01 Feb 2018 Planned number of patients changed from 18 to 16.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History